Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J-J Kiladjian

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Leukemia|May 12, 2016
Is there consensus on consensus?J-J Kiladjian, R P Gale
Leukemia|October 25, 2007
Defects of immune surveillance offer new insights into the pathophysiology and therapy of myelodysplastic syndromesJ-J Kiladjian, P Fenaux, A Caignard
Leukemia|November 26, 2015
Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant cloneJ-J Kiladjian, S Giraudier, B Cassinat
Leukemia|October 10, 2008
Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasmsJ-J Kiladjian, C Chomienne, P Fenaux
Bailliere'S Clinical Haematology|February 1, 1997
Megakaryocytes and platelets in myeloproliferative disordersJ Briere, J J Kiladjian, E Peynaud-Debayle
Comptes Rendus Des Seances De La Societe De Biologie Et De Ses Filiales|January 1, 1996
[Dysmegakaryocytopoiesis and dysthrombopoiesis in myeloproliferative syndromes]J Brière, J J Kiladjian, E Peynaud-Debayle
Pathologie-Biologie|August 12, 2006
The first international meeting on V617F JAK2 mutation and its relevance in Philadelphia-negative myeloproliferative disordersJ J Kiladjian, N Casadevall, W Vainchenker, et al.
Leukemia & Lymphoma|September 1, 1996
Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centersT Barbui, G Finazzi, E Dupuy, et al.
Leukemia|May 10, 2017
The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disordersN Maslah, B Cassinat, E Verger, et al.
Nephrologie|March 13, 2002
[Antibodies against human recombinant erythropoietin: an unusual cause of erythropoietin resistance]Béatrice Virón, A Kolta, J J Kiladjian, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Leukemia|May 12, 2016
Is there consensus on consensus?J-J Kiladjian, R P Gale
Leukemia|October 25, 2007
Defects of immune surveillance offer new insights into the pathophysiology and therapy of myelodysplastic syndromesJ-J Kiladjian, P Fenaux, A Caignard
Leukemia|November 26, 2015
Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant cloneJ-J Kiladjian, S Giraudier, B Cassinat
Leukemia|October 10, 2008
Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasmsJ-J Kiladjian, C Chomienne, P Fenaux
Bailliere'S Clinical Haematology|February 1, 1997
Megakaryocytes and platelets in myeloproliferative disordersJ Briere, J J Kiladjian, E Peynaud-Debayle
Comptes Rendus Des Seances De La Societe De Biologie Et De Ses Filiales|January 1, 1996
[Dysmegakaryocytopoiesis and dysthrombopoiesis in myeloproliferative syndromes]J Brière, J J Kiladjian, E Peynaud-Debayle
Pathologie-Biologie|August 12, 2006
The first international meeting on V617F JAK2 mutation and its relevance in Philadelphia-negative myeloproliferative disordersJ J Kiladjian, N Casadevall, W Vainchenker, et al.
Leukemia & Lymphoma|September 1, 1996
Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centersT Barbui, G Finazzi, E Dupuy, et al.
Leukemia|May 10, 2017
The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disordersN Maslah, B Cassinat, E Verger, et al.
Nephrologie|March 13, 2002
[Antibodies against human recombinant erythropoietin: an unusual cause of erythropoietin resistance]Béatrice Virón, A Kolta, J J Kiladjian, et al.
Pageof 5